This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jhaveri, M. S. Articles by Chang, E. H. Search for Related Content PubMed PubMed Citation Articles by Jhaveri, M. S. Articles by Chang, E. H.

¹ Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia; ² Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri; and ³ Medical Oncology Clinical Research Unit, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Esther H. Chang, Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Research Building, E420, 3970 Reservoir Road Northwest, Washington, DC 20007-2197. Phone: 202-687-8418; Fax: 202-687-8434. E-mail: change{at}georgetown.edu

Folates are essential for cell survival and are required for numerous biochemical processes. The human isoform folate receptor (hFR) has a very high affinity for folic acid and is considered an essential component in the cellular accumulation of folates and folate analogues used in chemotherapy. The expression of hFR is not detected inmost normal tissues. In contrast, high levels of the expression of hFR have been reported in a variety of cancer cells. The significance of hFR overexpression in malignant tissues has not been elucidated, but it is possible that it promotes cell proliferation not only by mediating folate uptake but also by generating other regulatory signals. The purpose of the present study was to evaluate hFR as a potential target for the treatment of breast cancer. Initial studies were done in nasopharyngeal carcinoma (KB) cells, which express high levels of hFR. In KB cells, antisense oligodeoxyribonucleotides (ODN) complementary to the hFR gene sequences were found to reduce newly synthesized hFR protein up to 60%. To examine the effect of hFR antisense ODNs in a panel of cultured human breast cancer cell lines, we used a tumor cell–targeted, transferrin-liposome–mediated delivery system. The data show that hFR antisense ODNs induced a dose-dependent decrease in cell survival. Finally, we determined that hFR antisense ODNs sensitized MDA-MB-435 breast cancer cells by 5-fold to treatment with doxorubicin. The data support the application of hFR antisense ODNs as a potential anticancer agent in combination with doxorubicin.

Key Words: doxorubicin • 07-06-02 antisense oligonucleotides

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/11/03; revised 9/23/04; accepted 10/ 7/04.

This article has been cited by other articles:

				T. R. Daniels, P. P. Ng, T. Delgado, M. R. Lynch, G. Schiller, G. Helguera, and M. L. Penichet Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells Mol. Cancer Ther., November 1, 2007; 6(11): 2995 - 3008. [Abstract] [Full Text] [PDF]

				K. L. Knutson, C. J. Krco, C. L. Erskine, K. Goodman, L. E. Kelemen, P. J. Wettstein, P. S. Low, L. C. Hartmann, and K. R. Kalli T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4254 - 4261. [Abstract] [Full Text] [PDF]

				V. Askoxylakis, S. Zitzmann, W. Mier, K. Graham, S. Kramer, F. von Wegner, R. H.A. Fink, M. Schwab, M. Eisenhut, and U. Haberkorn Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160 Clin. Cancer Res., September 15, 2005; 11(18): 6705 - 6712. [Abstract] [Full Text] [PDF]